Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 1:16 PM ET
DRUG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $541.93M
- EPS (TTM)
- -$2.05
- Dividend yield
- None
- 52-week range
- 47.23 – 123.75
- Day range
- 51.91 – 55.29
- Volume / Avg
- 52.01K / 159.01K
- Beta
- —
- Shares outstanding
- 9.86M
52-week range
DRUG stock today
Bright Minds Biosciences (DRUG) is trading at $54.94 on Oct 9, up 5.65% (+$2.94), versus the S&P 500's 0.52% gain. At this level, DRUG sits near the bottom of its 52-week range of $47.23 to $123.75: 55.6% below the high, set on Jan 6, 2026 and 16.3% above the low. DRUG is down 33.4% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 5.8%.
Bright Minds Biosciences has posted a net loss over the last twelve months (EPS of -$2.05), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Bright Minds Biosciences
Company profileBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ian McDonald
- Headquarters
- New York, NY
- Employees
- 26
- Website
- brightmindsbio.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$151.97+176.61%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Bright Minds Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EOLSEvolus Inc. | 7.74 | -0.77% | $511.23M | vs DRUG |
| CTNMContineum Therapeutics Inc. Class A | 13.50 | +2.43% | $507.89M | vs DRUG |
| ALTAltimmune Inc. | 2.60 | +0.10% | $506.27M | vs DRUG |
| ARVNArvinas Inc. | 7.72 | +2.73% | $497.78M | vs DRUG |
| OCSOculis Holding AG | 8.52 | -1.62% | $524.73M | vs DRUG |
| MPLTMapLight Therapeutics Inc. | 8.84 | -3.39% | $491.29M | vs DRUG |
| PBYIPuma Biotechnology Inc | 10.28 | +3.11% | $530.65M | vs DRUG |
| CTMXCytomX Therapeutics Inc. | 2.50 | +1.01% | $543.66M | vs DRUG |
Indexes, lists and sector
Bright Minds Biosciences stock FAQ
What is Bright Minds Biosciences's stock price today?
DRUG last traded at $54.94 as of Oct 9, 1:16 PM EDT, up 5.65% on the day. Prices are delayed at least 15 minutes.
Does Bright Minds Biosciences pay a dividend?
No. Bright Minds Biosciences does not currently pay a regular cash dividend.
Who is Bright Minds Biosciences's CEO?
Mr. Ian McDonald is the chief executive officer of Bright Minds Biosciences Inc., which has about 26 employees.
Has DRUG ever split its stock?
Yes. The most recent DRUG stock split was a 1-for-5 split on Jul 14, 2023.
What is the DRUG 52-week high?
The 52-week high for DRUG is $123.75 and the 52-week low is $47.23. The stock is currently 55.6% below its high.